Comparative Pharmacology
Head-to-head clinical analysis: CAPASTAT SULFATE versus TRECATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPASTAT SULFATE versus TRECATOR.
CAPASTAT SULFATE vs TRECATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Capastat sulfate (capreomycin) is a cyclic polypeptide antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, interfering with initiation and elongation steps.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the formation of the initiation complex and causing misreading of mRNA.
15 mg/kg (max 1 g) intramuscularly daily for 60-120 days.
15-20 mg/kg/day orally once daily; maximum 1 g/day.
None Documented
None Documented
3-6 hours; prolonged to 12-24 hours in renal impairment; negligible hepatic metabolism
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged in hepatic impairment; clinically relevant for once-daily or thrice-weekly dosing
Primarily renal (80-90% as unchanged drug via glomerular filtration); minor fecal (10-20%)
Renal: 70-80% as unchanged drug; fecal: <20%; biliary: minor
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent